Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Inclusion Criteria: Evaluable or measurable disease per RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy of ≥12 weeks Adequate hematologic and organ function within 14 days prior to initiation of study Inclusion Criteria for Non-Small Cell Lung Cancer Cohorts Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the lung that has progressed on/after prior treatment with third-generation epidermal growth factor receptor (EGFR) inhibitor (e.g., osimertinib) Positive for an EGFR exon 19 deletion or exon 21 L858R mutation Negative for acquired on-target EGFR alterations Inclusion Criteria for Colorectal Cancer Cohorts Histologically confirmed metastatic adenocarcinoma of the colon or rectum that has progressed on/after prior treatment with an EGFR inhibitor (e.g., cetuximab or panitumumab) Negative for kirsten rat sarcoma viral oncogene homolog (KRAS) alterations Negative for neuroblastoma RAS viral oncogene homolog (NRAS) alterations Negative for proto-oncogene B-Raf (BRAF) V600E alterations In lieu of a fresh pre-treatment biopsy, a recently obtained biopsy performed after completion of osimertinib therapy will be acceptable Exclusion Criteria: Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 3 weeks or 5 drug elimination half-lives, whichever is shorter, prior to initiation of study treatment Treatment with endocrine therapy within 2 weeks prior to initiation of study drug, except for hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for endocrine-sensitive cancers Significant traumatic injury or major surgical procedure within 4 weeks prior to Cycle 1, Day 1 Positive hepatitis C virus (HCV) antibody test at screening Positive hepatitis B surface antigen (HBsAg) test at screening Known HIV infection Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis Uncontrolled hypercalcemia Substance abuse, as determined by the investigator, within 12 months prior to screening Poor peripheral venous access Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteral absorption Chronic diarrhea, short bowel syndrome, or significant upper GI surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or any active bowel inflammation (including diverticulitis) Serious infection within 4 weeks prior to screening History of malignancy within 3 years prior to screening Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) Leptomeningeal disease or carcinomatous meningitis History or presence of an abnormal electrocardiogram (ECG) that is deemed clinically significant by the investigator (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence of prior myocardial infarction Left ventricular ejection fraction (LVEF) less than the institutional lower limit of normal (LLN) or <50% History or evidence of ophthalmic disease History of or active clinically significant cardiovascular dysfunction History of pulmonary firbrosis, organizing pneumonia, or pneumonitis Other protocol-defined inclusion/exclusion criteria may apply.